Due to the relationship between IL-6 and lethal pathology in viral infections, and due to the range of approved anti-IL-6 drugs available on the market for diseases including rheumatoid arthritis and multiple sclerosis (such as the IL-6 receptor antagonists tocilizumab and sarilumab or drugs that act directly on IL-6, sirukumab). Here, IL6 is linked to multiple sclerosis.